<DOC>
	<DOCNO>NCT02289924</DOCNO>
	<brief_summary>The main objective non-interventional cohort field study evaluate effectiveness Eylea describe follow-up well treatment pattern patient wAMD ( wet age-related macular degeneration ) routine clinical practice Italy study population `` naïve '' patient</brief_summary>
	<brief_title>Aflibercept ( Eylea ) roUtine Clinical Practice patientS With Wet Age-related Macular Degeneration Italy</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>`` Naïve '' patient wet AMD ( agerelated macular degeneration ) treat Eylea ( accordance local Summary Product Characteristics , SPC ) . Exclusion criterion list local SPC . Scar , fibrosis , atrophy involve center fovea study eye . Any concomitant therapy another agent treat wet AMD study eye . Any prior concomitant therapy another drug wAMD .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>wet AMD</keyword>
</DOC>